![Johan Hyllner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Johan Hyllner
Former positions of Johan Hyllner
Companies | Position | Start | End |
---|---|---|---|
Cell Therapy Catapult Ltd.
![]() Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01/05/2013 | 21/06/2018 |
PHASE HOLOGRAPHIC IMAGING PHI AB | Director/Board Member | 01/01/2017 | 02/01/2017 |
Takara Bio Europe AB
![]() Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Chief Operating Officer | 01/01/2001 | 16/09/2011 |
Chief Tech/Sci/R&D Officer | 01/01/2001 | 01/02/2013 | |
President | 16/09/2011 | 09/01/2012 | |
VITROLIFE AB | Chief Tech/Sci/R&D Officer | - | 01/01/2002 |
HCL TECHNOLOGIES LIMITED | Director/Board Member | 01/01/2017 | - |
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Director/Board Member | 03/09/2010 | - |
Statistics
International
Sweden | 4 |
United Kingdom | 3 |
India | 2 |
Operational
Chief Tech/Sci/R&D Officer | 3 |
Director/Board Member | 3 |
Chief Operating Officer | 1 |
Sectoral
Health Technology | 5 |
Commercial Services | 2 |
Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
VITROLIFE AB | Health Technology |
HCL TECHNOLOGIES LIMITED | Technology Services |
PHASE HOLOGRAPHIC IMAGING PHI AB | Health Technology |
Private companies | 3 |
---|---|
Takara Bio Europe AB
![]() Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
Cell Therapy Catapult Ltd.
![]() Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Johan Hyllner
- Experience